Celldex Therapeutics, Inc.
CLDXDrugs in Pipeline
17
Phase 3 Programs
3
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
4 upcoming, 0 past
How CLDX's past catalysts played out
Rindopepimut (CDX-110) with GM-CSF
Glioblastoma
barzolvolimab
Prurigo Nodularis
KLH
Glioblastoma
CDX-011
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Ovarian Clear Cell Adenocarcinoma
CDX-110 with GM-CSF
Malignant Glioma
"Investigator's Choice" chemotherapy
Breast Cancer
NeoAg-mBRAF
Melanoma
FLT3 Ligand Therapy (CDX-301)
Non-small Cell Lung Cancer (NSCLC)
Human CMV pp65-LAMP mRNA-pulsed autologous DCs
Glioblastoma
DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Fallopian Tube Carcinoma
Varlilumab
B Cell Lymphoma
CDX-301
Breast Cancer
rhuFlt3L/CDX-301
Low-Grade B-cell Lymphoma
Flt3L
Non-Hodgkin's Lymphoma
6MHP
Melanoma
CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Advanced Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Rindopepimut (CDX-110) with GM-CSF | Phase 3 | Glioblastoma | - | - |
barzolvolimab | Phase 3 | Prurigo Nodularis | - | - |
KLH | Phase 3 | Glioblastoma | - | - |
CDX-011 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | - | - |
Anti-CD40 Agonist Monoclonal Antibody CDX-1140 | Phase 2 | Ovarian Clear Cell Adenocarcinoma | - | - |
CDX-110 with GM-CSF | Phase 2 | Malignant Glioma | - | - |
"Investigator's Choice" chemotherapy | Phase 2 | Breast Cancer | - | - |
NeoAg-mBRAF | Phase 2 | Melanoma | - | - |
FLT3 Ligand Therapy (CDX-301) | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Phase 2 | Glioblastoma | - | - |
DEC-205/NY-ESO-1 Fusion Protein CDX-1401 | Phase 2 | Fallopian Tube Carcinoma | - | - |
Varlilumab | Phase 2 | B Cell Lymphoma | - | - |
CDX-301 | Phase 2 | Breast Cancer | - | - |
rhuFlt3L/CDX-301 | Phase 2 | Low-Grade B-cell Lymphoma | - | - |
Flt3L | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
6MHP | Phase 2 | Melanoma | - | - |
CDX-1401 in combination with Resiquimod and/or Poly-ICLC | Phase 2 | Advanced Malignancies | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Celldex Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in Celldex Therapeutics, Inc.'s (CLDX) pipeline across Phase 3, Phase 2. Its lead program is Rindopepimut (CDX-110) with GM-CSF (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celldex Therapeutics, Inc.'s next FDA catalyst?→
Celldex Therapeutics, Inc.'s (CLDX) next tracked catalyst is a Phase 2 expected December 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLDX biotech catalysts?→
Add CLDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celldex Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.